Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing high-throughput biological discoveries and therapeutic development.
High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, HCS imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of assays involving complex cellular disease models.
There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of HCS assays today; the motivation to purchase assays kits versus developing homebrew; the use of specialty microplates; spending on HCS assays, reagents and consumables; and what is needed to expand the market for HCS assays. This is explored with respect to enhanced vendor offerings in HCS-engineered microplates, microchannel plates, new cell models incorporating HCS, new assay dyes and reagents, and new HCS assay kits. We conclude that HCS assay development has never been more accessible and supported by such a diversity of off-the-shelf products.